Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: Topical Tofacitinib therapy with Excimer light: Topical Tofacitinib gel/ointment in a concentration of 2% twice daily on the prescribed area and excimer light will be administered in a
Sponsors
Dr Imran Majid
Dr Sehar Imran
Eligibility
Inclusion criteria
Inclusion criteria: Participants of age group 12 to 70 years to be included. Patients with a confirmed diagnosis of vitiligo for any duration, Bilaterally symmetrical lesions of vitiligo present on any part of the body, Involving less than 5% of Body Surface area, Patients eligible for Excimer light therapy for vitiligo, Washout period of 1 week in case of topical therapy for Vitiligo and 1 month washout period for Systemic therapy for vitiligo before enrolment, Written informed consent signed by the patient or legally acceptable representative(s) in line with applicable regulation of country, Planned treatment in line with the Summary of Product Characteristics
Exclusion criteria
Exclusion criteria: any contraindication to any of the topical medications &/or Excimer therapy, women of childbearing age, pregnancy, lactation, hypersensitivity to any of the topical agents, unwillingness to conform to study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the repigmenting efficacy of a combination of Excimer light with topical Tofacitinib versus Excimer light with placebo in vitiligoTimepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| To obtain safety information in terms of adverse events on the use Excimer light with topical Tofacitinib versus Excimer light with placebo in vitiligoTimepoint: 1 year | — |
Countries
India
Contacts
Public ContactDr Imran Majid
Cutis Institute of Dermatology
Outcome results
None listed